Big Upside for WellPoint, Managed Care Stocks

September 8, 2009

Carl McDonald of Oppenheimer sees a big upside for shares in WellPoint — and a solid outlook for managed care stocks in general.  You can watch McDonald’s comments in this video from the Nasdaq Market Site.

The thing to remember is that the key driver for managed care stocks is the realization among investors that healthcare reform isn’t going to put the industry out of business.  That’s true even if we get a public option; it’s doubly true since it’s almost certain we’re not going to get a public option.


Severe Punishment to Pfizer

September 4, 2009

It seems that federal prosecutors decided to throw the book (and then some) at the pharmaceutical giant Pfizer with a record-breaking $2.3 billion in fines for promoting so-called off-label uses of some of its drugs, most notably the arthritis drug Bextra.  Pfizer was also called a repeating corporate cheat for illegal drug promotions that supplied doctors with free golf, massages, and resort junkets. The latter are indefensible, but the off-label prescribing issue deserves some reflection. 

A drug is approved by the FDA for a very specific medical condition and companies are prohibited from promoting the drug for any other (unapproved) indications.  So if a drug like Bextra is approved to treat arthritis the company cannot promote the drug for the treatment of post-surgical pain without FDA approval, even if there are data within scientific publications suggesting its possible benefits for this second indication.  This is done often (though not always) for good reasons – avoiding the use of drugs with unknown effects (good or bad) in a new disease.  But here is the kicker: physicians are allowed to prescribe any drug any time for any medical condition – whether the drug is approved or not for that condition. So the law permits drug companies to send information (mostly publications) on off-label effects of drugs only after physicians have requested it.  The entire debate, then, in this off-label debate is where and how should physicians get the information that will enable them to prescribe drugs marketed for other uses, something they can do freely. 

While there is a basic logic to the legislation (preserving physicians’ freedom but retaining reasonable regulation power to the FDA), this law seems too convoluted and can lead sometimes to ridiculous exchanges between physicians and pharmaceutical sales reps (who mentioned the off-label use first? Did the doc ask for a publication or did the rep volunteer to send it?).  Any massive marketing campaign to promote an off-label use should, of course, be banned.  Any one-on-one interaction between rep and doctor should be only of interest to regulators if the off-label use led to a serious harm, in which case the physician should be more liable than he otherwise would. 

The amount that Pfizer has to pay, while “affordable,” is extensive and is designed to punish it, as well as deter others.  With net income of $8.1 billion in 2008 (out of more than $48 billion revenues) this is a painful hit that will likely change Pfizer’s future behavior.  On the other hand, one has to wonder whether applying $2.3 billion to R&D or investing it in other biotech drugs in development would have served our public better.


German Healthcare a Model for the U.S.

September 3, 2009

Forbes has a very good article on Germany’s universal healthcare system, which combines public and private insurance and could be a model for the U.S.  I’ve often wondered why the German system gets so little attention in the U.S.  Germany spends about 10% of its GDP on healthcare (vs. 16% in the U.S.) – despite having an older population — and costs adjusted for inflation are rising just 1.4% annually.  The German system has very high satisfaction levels and achieves superior results to the U.S. based on measures such as life expectancy, infant mortality and obesity rates.  Writes Forbes:

This is close to, but not fully, socialized medicine. The public insurance system is largely financed by a payroll tax amounting to 14.9% of a person’s salary, with employees picking up 7.9% and employers taking the rest. As for disability, employers pay six weeks’ salary; after that the sickness fund, or nonprofit insurer, pays 80%, subject to a cap, for 18 months. This year the government will kick in an additional $10.3 billion to help cover children, maternity benefits and home help. Unemployment insurance pays the fees for those out of a job. Premiums in the public system are based on income and not an individual’s risk (that is, age and current health). It’s a different story for those with private insurance, where high-risk people pay higher premiums. There are sometimes deductibles in the private system, but public patients have only copays.

How does Germany do it? By doing what Medicare does and more. It sets fixed reimbursement rates for hospitals and wields a stick Medicare lacks: extracting price concessions from drug companies.


Obama Takes on Healthcare Reform Myths

September 2, 2009

If you want an indication of what Obama is likely to say in his healthcare reform speech reportedly set for next week, take a look at his weekly address from Aug. 21.  My guess is the tenor will be the same.


Obama To Take New Tack on Healthcare Reform?

September 2, 2009

President Obama is reportedly going to make a major speech next week outlining a new strategy to counter opposition to health reform, including potential areas of compromise, according to Reuters.

As much as I like and support Obama, I don’t expect any major changes in his approach.  He’s a consensus builder by nature; although I wouldn’t mind seeing him come out swinging. 

The big question is whether he will say outright that the public plan is off the table — or simply doom it by omission.  Notes Wachovia analyst Matt Perry:

The speech is likely a response to the loss of momentum that has occurred over the Congressional recess….Momentum has shifted to such a degree that a public plan is now unlikely to be implemented, in our view. Obama needs more public support to pass health care reform. To turn the tide, we expect compromises in the coming weeks. Obama’s speech next week may be the first concrete sign of compromise. 


Follow

Get every new post delivered to your Inbox.